| Identification | Back Directory | [Name]
GLPG-1690 | [CAS]
1628260-79-6 | [Synonyms]
CS-2644
GLPG-1690
GLPG11690
ziritaxestat
GLPG 1690;GLPG1690
GLPG-1690 USP/EP/BP
GLPG-1690; GLPG 1690; GLPG1690; ZIRITAXESTAT.
2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile
5-Thiazolecarbonitrile, 2-[[2-ethyl-6-[4-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]-1-piperazinyl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)- | [Molecular Formula]
C30H33FN8O2S | [MDL Number]
MFCD31544330 | [MOL File]
1628260-79-6.mol | [Molecular Weight]
588.7 |
| Chemical Properties | Back Directory | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:70.84(Max Conc. mg/mL);120.32(Max Conc. mM)
Ethanol:4.0(Max Conc. mg/mL);6.79(Max Conc. mM) | [form ]
A crystalline solid | [pka]
13.72±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
GLPG1690 is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement. |
|
|